Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing
7.3.2023 12:00:00 EET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx. USD 112 million) Series B financing round. Sofinnova co-founded and seed financed Noema in 2019 with Dr. George Garibaldi and Luigi Costa. The company was established to advance clinical stage assets in-licensed from Roche.
Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus welcomed new investors Forbion and Jeito Capital, as well as UPMC Enterprises and another undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor that is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The company is also developing gemlopodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “As co-founders and initial investors of Noema, we are incredibly proud of what the company has accomplished since its inception. Raising an oversubscribed funding round of this magnitude is a significant achievement that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders . Noema is the perfect illustration of our core strategy and expertise: we nurture innovative companies centered on groundbreaking science and exceptional talent that have the potential to deliver transformative results for patients.”
Luigi Costa, Chief Executive Officer of Noema Pharma, said: "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005296/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datang Mobile, KPN, NEC and Wilus are Latest Licensors to Join Sisvel POS Patent Pool as Incentive Deadline Nears5.5.2026 11:02:00 EEST | Press release
Datang Mobile, KPN, NEC and Wilus have become the latest licensors in the Sisvel point of sale (POS) patent pool. They join seven other patent owners in making their 2G-5G cellular portfolios available through the programme: BlackBerry, Huawei, JVCKENWOOD, LG Electronics, Nokia, Sisvel and SK Telecom. The period for Sisvel POS licensors to benefit from early participation incentives is set to close on 15 May. Cellular patent owners interested in becoming involved should contact Sisvel as soon as possible. The pool, which is the first in the market to address the POS vertical, was announced at the beginning of April, with Huawei, LG Electronics and Nokia as founding licensors. “We have received a great response from the market so far, and I am pleased to welcome Datang, KPN, NEC and Wilus as the latest licensors,” says POS programme manager Sven Törringer. “We have put together a formidable group of cellular technology innovators, and there are many more companies in the pipeline. I am
Bregal Milestone Announces Majority Growth Investment in meteoviva, an AI-Powered Building Energy Management Solution5.5.2026 11:01:00 EEST | Press release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in meteoviva GmbH (“meteoviva” or the “Company”), a pioneer in AI-powered predictive building energy management. meteoviva's intelligent solutions combine a proprietary physics-based thermodynamic model with AI to deliver energy cost reductions of up to 45 percent across large-scale commercial real estate portfolios, without structural retrofits. meteoviva is widely recognised as a market leader in autonomous building energy management, with over 500 buildings across 19 countries, accounting for 11.5 million square metres of real estate under active control. Its customer base includes some of Europe's most demanding buildings, among them Germany's largest office building, The Squaire at Frankfurt Airport, the BMW Group IT Centre in Munich, and the DC Tower in Vienna. meteoviva is the first provider in its category certified by the German Sustainable Building Council (D
OCTO and Sedgwick Announce Strategic Telematics Partnership5.5.2026 11:00:00 EEST | Press release
OCTO, a global leader in telematics and data analytics, today announced a strategic partnership with Sedgwick, the world’s leading provider of claims and risk management solutions. Together, the two companies will reshape the future of insurance and mobility by combining advanced telematics with claims management services. The collaboration aims to create a new model where telematics and efficiency come together to transform the customer experience. By integrating OCTO’s cutting-edge telematics insights with Sedgwick’s global expertise in claims handling, the partnership will unlock a series of tangible benefits: enhanced speed and accuracy in crash and claims intake, quicker and more consistent liability assessments, fraud validation and reduction, optimized alerts to improve driver safety, and significant reductions in the overall cost and lifecycle of claims. The joint solution is telematics-agnostic, able to ingest data from connected cars, fleet management systems, or OCTO’s own o
Schindler Selects Navan to Elevate Global Travel Operations5.5.2026 11:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today announced it has been selected by Schindler, the leading provider of sustainable and smart urban mobility, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505725595/en/ Leading provider of sustainable and smart urban mobility deploys Navan to deliver a seamless experience for its workforce With over 150 years of industry innovation, Schindler has reshaped mobility in urban societies, growing from a local manufacturer into a global elevator, escalators and moving walkways business. To support its next phase of growth, the company has chosen to consolidate its travel operations – moving away from a fragmented online booking model. By deploying Navan, Schindler is now unifying its travel management across North America and Europe, initially covering Canada, the United States, France, Portu
euroAtlantic Airways Appoints Pauls Calitis as CEO to Lead Next Phase of Growth5.5.2026 10:00:00 EEST | Press release
euroAtlantic Airways (“EAA”), a leading global provider of passenger widebody aircraft wet-leasing and charter services, and Njord Partners portfolio company, is pleased to announce the appointment of Pauls Calitis as Chief Executive Officer, effective 18 May 2026. Pauls will succeed Stewart Higginson, who has served as CEO since early 2024 and who will assume the role of Non-Executive Chairman of the Board. The appointment marks the next phase of the company’s development under Njord Partners. Pauls brings more than three decades of expertise in the aviation industry, most recently serving as Chief Operating Officer and Executive Board Member at airBaltic, having also held the role of Interim Chief Executive Officer in 2025. Over his career progressing from pilot to senior executive leadership, he played a central role in the airline’s development and transformation into one of Europe’s most efficient and respected carriers. His leadership helped establish the airline as a benchmark f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom